Clinical Trial Update: SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for SHR-A1811 in HER2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma after progression on prior anti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• SHR-A1811

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: RECRUITING